Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 6

1.

Inducible silencing of protein kinase D3 inhibits secretion of tumor-promoting factors in prostate cancer.

LaValle CR, Zhang L, Xu S, Eiseman JL, Wang QJ.

Mol Cancer Ther. 2012 Jul;11(7):1389-99. doi: 10.1158/1535-7163.MCT-11-0887. Epub 2012 Apr 24.

PMID:
22532599
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Design, Synthesis, and Biological Evaluation of PKD Inhibitors.

George KM, Frantz MC, Bravo-Altamirano K, Lavalle CR, Tandon M, Leimgruber S, Sharlow ER, Lazo JS, Wang QJ, Wipf P.

Pharmaceutics. 2011;3(2):186-228. doi: 10.3390/pharmaceutics3020186.

PMID:
22267986
[PubMed]
Free PMC Article
3.

Synthesis and Structure-Activity Relationships of Benzothienothiazepinone Inhibitors of Protein Kinase D.

Bravo-Altamirano K, George KM, Frantz MC, Lavalle CR, Tandon M, Leimgruber S, Sharlow ER, Lazo JS, Wang QJ, Wipf P.

ACS Med Chem Lett. 2011 Feb 14;2(2):154-159.

PMID:
21617763
[PubMed]
Free PMC Article
4.

Protein kinase D as a potential new target for cancer therapy.

LaValle CR, George KM, Sharlow ER, Lazo JS, Wipf P, Wang QJ.

Biochim Biophys Acta. 2010 Dec;1806(2):183-92. doi: 10.1016/j.bbcan.2010.05.003. Epub 2010 May 24. Review.

PMID:
20580776
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Novel protein kinase D inhibitors cause potent arrest in prostate cancer cell growth and motility.

Lavalle CR, Bravo-Altamirano K, Giridhar KV, Chen J, Sharlow E, Lazo JS, Wipf P, Wang QJ.

BMC Chem Biol. 2010 May 5;10:5. doi: 10.1186/1472-6769-10-5.

PMID:
20444281
[PubMed]
Free PMC Article
6.

Potent and selective disruption of protein kinase D functionality by a benzoxoloazepinolone.

Sharlow ER, Giridhar KV, LaValle CR, Chen J, Leimgruber S, Barrett R, Bravo-Altamirano K, Wipf P, Lazo JS, Wang QJ.

J Biol Chem. 2008 Nov 28;283(48):33516-26. doi: 10.1074/jbc.M805358200. Epub 2008 Sep 30.

PMID:
18829454
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk